Caruso's Natural Health Pty Limited – Trademark Portfolio

Entity Type: 99

Caruso's Natural Health Pty Limited holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include ERECTOMAX, TESTOROID, CARUSO'S PEE LESS, and CARUSO'S NATURAL HEALTH. The owner is based in Eastern Creek, NSW.

14 Shale Place

Eastern Creek, NSW 2766 , AU

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Caruso's Natural Health Pty Limited's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Caruso's Natural Health Pty Limited have?

Caruso's Natural Health Pty Limited has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.

What trademark classes does Caruso's Natural Health Pty Limited file in?

Caruso's Natural Health Pty Limited files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Caruso's Natural Health Pty Limited's most well-known trademarks?

Caruso's Natural Health Pty Limited's registered trademark portfolio includes well-known marks such as ERECTOMAX, TESTOROID, CARUSO'S PEE LESS, and CARUSO'S NATURAL HEALTH. These are among 4 currently registered trademarks in the portfolio.

What is Caruso's Natural Health Pty Limited's trademark registration success rate?

Caruso's Natural Health Pty Limited has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.